0001628280-26-022010
SEC filingIntensifying losses and cash burn marked FY2025 for this clinical-stage biotech, driven by R&D ramp for later-stage ficerafusp alfa trials amid no revenue since 2018 inception, buffered by equity financing from common stock sales.
Net losses widened significantly to -$137.9M in FY2025 from -$68.0M the prior year, a -102.9% change, as therapeutic candidates like ficerafusp alfa progressed to later stages of clinical development. These stages inherently carry higher costs due to the increased size and duration of trials, driving the expected escalation in research and development expenses for the foreseeable future.
The increase in cash, cash equivalents, and marketable securities stemmed primarily from common stock sales, enabling funding of these operations and providing additional liquidity as market conditions permit through mechanisms like the ATM Program. This equity financing countered the heightened investing outflows tied to large purchases of short-term and long-term U.S. marketable securities, a conservative strategy to preserve capital post-raises.
Management views existing cash, cash equivalents, and marketable securities—including net proceeds from the February 2026 Offering—as sufficient to fund operations and capital expenditure requirements into the first half of 2029 under current plans. This runway supports planned substantial increases in R&D expenses to advance ficerafusp alfa and potential other candidates, alongside rising general and administrative costs to underpin expanded activities. Stock-based compensation, recognized as grant date fair value over vesting periods, remains a key non-cash element in the expense profile.
Overall, FY2025 underscores a deliberate investment phase in clinical advancement without revenue offset, positioning Bicara for potential milestones while maintaining disciplined cash management through equity inflows and securities deployment.